Roche Holdings AG RHHBY on Monday outlined its plan to become a leading player in the surging weight-loss drug market, pushing its obesity pipeline farther into late-stage development as it eyes competition with Eli Lilly And Co. LLY and Novo Nordisk A/S NVO.The company announced it had advanced CT-388, its experimental obesity treatment, into a Phase 3 trial.The therapy entered Roche's pipeline through its 2023 acquisition of Carmot Therapeutics.RHHBY is demonstrating bullish strength. Follow the breaking ...